Steglujan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0025/G 
This was an application for a group of variations. 
18/09/2023 
SmPC and PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.e.5.b - Implementation of changes foreseen in an 
approved change management protocol - Requires 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
further supportive data 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.c.1.f - Change in the specification parameters 
and/or limits of an excipient - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter with its 
corresponding test method as a result of a safety or 
quality issue 
B.II.c.1.f - Change in the specification parameters 
and/or limits of an excipient - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter with its 
corresponding test method as a result of a safety or 
quality issue 
WS/2537 
This was an application for a variation following a 
31/08/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IG/1640 
B.I.b.1.d - Change in the specification parameters 
28/08/2023 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1613 
B.I.b.1.d - Change in the specification parameters 
19/06/2023 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IG/1623 
B.II.b.2.c.1 - Change to importer, batch release 
16/06/2023 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Annex II and 
PL 
IG/1606/G 
This was an application for a group of variations. 
11/05/2023 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/2390 
This was an application for a variation following a 
30/03/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
IAIN/0020/G 
This was an application for a group of variations. 
15/12/2022 
SmPC, Annex 
II and PL 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
R/0018 
Renewal of the marketing authorisation. 
15/09/2022 
05/12/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Steglujan in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10784
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202112 
ertugliflozin / metformin, ertugliflozin / sitagliptin, 
ertugliflozin 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0015 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
16/09/2021 
18/11/2021 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
IG/1426 
A.7 - Administrative change - Deletion of 
03/08/2021 
n/a 
manufacturing sites 
WS/1825 
This was an application for a variation following a 
23/07/2020 
16/11/2021 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/10784
Periodic Safety Update EU Single assessment - 
09/07/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
ertugliflozin / metformin, ertugliflozin / sitagliptin, 
ertugliflozin 
IB/0013 
B.I.b.1.h - Change in the specification parameters 
06/04/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
IG/1211 
B.I.a.3.a - Change in batch size (including batch size 
27/02/2020 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10681
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
/201906 
ertugliflozin / sitagliptin 
IG/1157 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/11/2019 
12/05/2020 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
PSUSA/10681
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
ertugliflozin / sitagliptin 
WS/1590 
This was an application for a variation following a 
23/05/2019 
12/05/2020 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
PSUSA/10681
Periodic Safety Update EU Single assessment - 
31/01/2019 
02/04/2019 
Refer to Scientific conclusions and grounds recommending 
/201806 
ertugliflozin / sitagliptin 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10681/201806. 
WS/1488 
This was an application for a variation following a 
14/02/2019 
n/a 
No changes to the product information are warranted at 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Submission of the final CSR for Study P007/1017 - a 
Phase 3, randomized, double-blind, placebo-
controlled, 26-week multicenter study with a 78-
week extension to evaluate the efficacy and safety of 
ertugliflozin in subjects with type 2 Diabetes Mellitus 
and inadequate glycaemic control on metformin 
monotherapy - together with the final summarized 
present. The RMP will be updated at the next opportunity. 
The benefit/risk ration for Steglatro, Steglujan and 
Segluromet is unchanged. 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
data of all adjudicated confirmed fractures from the 
broad pool and pooled 2-year safety data from the 7 
completed Phase 3 studies, including both 2-year 
studies P007/1017 and P002/1013. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
T/0004 
Transfer of Marketing Authorisation 
12/07/2018 
23/08/2018 
SmPC, 
Labelling and 
PL 
IB/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/06/2018 
23/08/2018 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0002 
B.I.b.2.b - Change in test procedure for AS or 
29/05/2018 
n/a 
starting material/reagent/intermediate - Deletion of 
a test procedure for the AS or a starting 
material/reagent/intermediate, if an alternative test 
procedure is already authorised 
IB/0001/G 
This was an application for a group of variations. 
26/04/2018 
23/08/2018 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 8/8 
 
 
 
 
 
 
 
